Rajasekaran, A., Julian, B. A. & Rizk, D. V. IgA nephropathy: an interesting autoimmune kidney disease. Am. J. Med. Sci. 361, 176–194 (2021).
Rovin, B. H. et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 100, 753–779 (2021).
Inker, L. A. et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am. J. Kidney Dis. 78, 340–349.e1 (2021).
Article CAS PubMed PubMed Central Google Scholar
Mathur, M. et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N. Engl. J. Med. 390, 20–31 (2024).
Article CAS PubMed Google Scholar
Lafayette, R. et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 105, 1306–1315 (2024).
Article CAS PubMed Google Scholar
Barratt, J. et al. Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000541 (2024).
Perkovic, V. et al. Alternative complement pathway inhibition with iptacopan in IgA nephropathy. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2410316 (2024).
Lafayette, R. et al. Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000534 (2024).
Heerspink, H. J. L. et al. Atrasentan in patients with IgA nephropathy. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2409415 (2024).
Heerspink, H. J. L. et al. The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial. J. Am. Soc. Nephrol. https://doi.org/10.1681/ASN.0000000538 (2024).
留言 (0)